Subscribe
Share
Share
Embed
Truth Seekers: Where Data Meets Reality
Tired of sensational headlines and conflicting health advice? Join Alex Barrett and Bill Morrison as they cut through the noise to uncover what scientific research actually says about the claims flooding your social media feed.
Each week, Alex and Bill tackle a different health, nutrition, or wellness claim that everyone's talking about. From "blue light ruins your sleep" to "seed oils are toxic," they dig into the actual studies, examine the methodologies, and translate the data into plain English.
No agenda. No sponsors to please. No credentials to fake. Just two people committed to finding out what's really true by going straight to the source—the research itself.
Perfect for anyone who's skeptical of influencer health advice but doesn't have time to read every scientific study themselves. New episodes drop regularly, delivering clarity in a world full of clickbait.
Question everything. Verify with data. Find the truth.
Disclaimer: Truth Seekers provides educational content based on published research. Nothing in this podcast should be considered medical, financial, or professional advice. Always consult qualified professionals for decisions affecting your health and wellbeing.
**The Petri Dish Promise: What That Viral Exercise-Cancer Study Actually Found**
Alex: "Just ten minutes of hard exercise sends powerful anti-cancer signals through your bloodstream." I saw that headline last week and I genuinely thought — okay, that's extraordinary. Ten minutes?
Bill: That was everywhere. My feeds were just drowning in it. And I'll be honest, even I felt a little pull of excitement before I actually read the study.
Alex: Which is exactly what worries me. Because when a claim is that clean, that perfectly shaped for a headline — "ten minutes, powerful anti-cancer effects" — my old journalism brain starts twitching.
Bill: It's the kind of story that travels because it's telling people something they desperately want to hear. The fix is easy, accessible, something they can do today.
Alex: And cancer is... I mean, almost everyone listening has a reason to care about this personally.
Bill: Right.
Alex: That's the thing. It touches most families. So when a headline like this lands, people aren't just curious — they're hopeful. And that hope deserves honesty.
Bill: It really does. Because the actual study is genuinely interesting. It's just not what the headlines say it is. Not even close.
Alex: Right, so walk me through it. What did they actually do?
Bill: Okay. So the study came out of Newcastle University — published in the International Journal of Cancer, late 2025. Thirty healthy volunteers, ages fifty to seventy-eight. They did a roughly ten-minute maximal intensity cycling test — genuinely hard, not a stroll. Blood samples collected before and immediately after.
Alex: Alright, so far that tracks with the headline. Exercise, blood, signals...
Bill: Hold on, hold on. Here's where it gets interesting. They didn't track what happened inside those thirty people's bodies over time. What they did was take the post-exercise blood, extract the serum —
Alex: The serum being the liquid part?
Bill: Right, no cells — just the liquid. And then they put that serum onto cancer cells. In a lab dish.
Alex: Sorry — they put the blood onto cancer cells... in a petri dish?
Bill: A petri dish, yes.
Alex: Huh.
Bill: The cancer cells were never inside a human. No cancer patient was involved in this study at any point. Thirty healthy people exercised, their blood was drawn, and that blood serum was used almost like a pharmaceutical — applied directly to isolated colon cancer cells in a controlled lab environment.
Alex: That is such a wildly different thing to what the headline implies. "Exercise sends powerful signals to cancer cells" — I'm picturing someone's body, blood moving, a tumour responding. Not a dish in a laboratory in Newcastle.
Bill: Exactly. And when they applied that serum to the cancer cells, they found something genuinely remarkable — for a mechanistic study. Over thirteen hundred genes changed their activity in those cancer cells. Some genes involved in rapid cell division dialled down. Some genes involved in DNA repair actually increased.
Alex: Okay.
Bill: In a petri dish, the post-exercise serum appeared to suppress cancer cell growth.
Alex: And... does that mean exercise fights cancer in the body?
Bill: That is the question this study specifically cannot answer. And — okay, I want to nerd out for a second here, because there's a distinction that almost never makes it into the coverage and it drives me absolutely mad.
Alex: Go on then.
Bill: So in science there are these two terms. In vitro — Latin for "in glass" — which means the experiment happened outside a living body, in lab equipment. And in vivo, "in the living," which means inside an actual organism. This Newcastle study is one hundred percent in vitro.
Alex: Right.
Bill: And I know Latin phrases can feel like a minor technical detail, but the gap between those two things is genuinely enormous. It's — actually, there's a reason we even have separate words for it.
Alex: Because they behave that differently?
Bill: So differently that we essentially treat them as different categories of evidence. Which, now that I think about it, is sort of interesting because the terminology only really got standardised in the twentieth century, even though people had been doing lab experiments on cells for decades before that —
Alex: Bill.
Bill: Yeah, sorry, that's a whole other thing. The point is — enormous gap. How enormous?
Alex: That's what I was going to ask, yes.
Bill: Okay, so. When we look at promising findings from lab studies — even animal studies, which are already a step closer to humans than a petri dish — somewhere between eighty-nine and ninety-five percent of them fail to translate into human treatments. And then even for cancer drugs that look promising enough to enter clinical trials —
Alex: Wait, I thought it was around ninety percent of lab findings that fail, not eighty-nine to ninety-five?
Bill: No, it's actually the range I said — eighty-nine to ninety-five — and then separately, over ninety-five percent of cancer drugs that get far enough to enter clinical trials still fail FDA approval. So there are two different failure rates stacked on top of each other. We're not even at the clinical trial stage with this study.
Alex: Right, okay. So the vast majority of things that look incredible in a lab never become anything in a human body.
Bill: The vast majority. Not because the science is bad — because biology in a dish and biology in a living person are completely different problems.
Alex: Although — and I want to push back on this slightly — doesn't that just make it sound like the study shouldn't have been done? Because those failure rates sound almost damning.
Bill: No, no — this is actually where I think I'd push back on you.
Alex: Go on then.
Bill: Those failure rates aren't an indictment of this study. That's how basic science is supposed to work. You don't skip petri dishes and go straight to cancer patients — that would be genuinely dangerous and unethical. The petri dish is step one. You're supposed to have a ninety percent attrition rate as you move up the evidence ladder. The problem isn't that this study exists; it's that the headline pretends it's the last rung, not the first.
Alex: Okay. Yeah, that's — that's fair, actually. I was reading those numbers as a failure of the research, and you're right, they're not. They're a feature of the process.
Bill: Exactly. The process working correctly looks like a lot of things failing at early stages. That's the filter doing its job.
Alex: Right. Okay, I'll concede that. But — and there's a specific reason this particular step is such a big leap, isn't there? You mentioned the tumour environment earlier.
Bill: Yeah, this is key. In a petri dish you have cancer cells in a sterile, controlled environment — just the cells and the serum they were bathed in for twenty-four hours. In an actual human body, a tumour is surrounded by other cell types, blood vessels, immune cells, connective tissue. The immune system is constantly interacting with it. Hormones are fluctuating. Organ systems are involved. That complexity is what makes cancer so hard to treat, and a petri dish doesn't capture any of it.
Alex: So applying serum to isolated cancer cells in a dish is almost like — testing whether a fire extinguisher works by spraying it on a single burning photograph, rather than an actual house fire.
Bill: That's... actually quite good.
Alex: Thank you.
Bill: You might successfully put out the photograph. That tells you almost nothing about the house.
Alex: And here's what really gets me — because this is the pattern I watched play out over and over again when I was covering health stories. The actual press release from Newcastle used very careful language. It said these findings "could lead to new therapies that imitate or augment the biological effects of exercise." Could. Might. Opens the door to.
Bill: Mmm.
Alex: That's the scientists being appropriately humble about what they actually proved.
Bill: Those words are doing enormous scientific work. "Could lead to future research" is a fundamentally different claim from "triggers powerful anti-cancer effects in your body."
Alex: By the time it hits a headline, "could" becomes "does." The conditional tense just vanishes. And I remember watching this happen in real time when I was in the newsroom — a wire story would come through, the original would say "may be associated with," and by the time it got a headline it was "causes." Every single time. The subeditors weren't being malicious, they were just — headlines need certainty. Uncertainty doesn't click.
Bill: And millions of people read the headline. Almost none of them read the methodology.
Alex: Almost none.
Bill: I used to be on the data side of exactly this dynamic, and it's uncomfortable to admit. When I was doing analytics work, the way findings got packaged for maximum reach almost always involved stripping out the uncertainty. And that's where all the important information lives.
Alex: Now — I want to be clear about this, because I think it matters — the researchers themselves aren't the villains here. The study is legitimate science. Dr. Orange at Newcastle is doing exactly what basic mechanistic research should do: identifying a potential pathway that might explain something bigger.
Bill: Completely. And the broader claim — that exercise protects against cancer — is actually solid. There's strong epidemiological evidence, the kind where you follow large populations over years and decades, showing that regular exercise reduces colorectal cancer risk by around twenty to twenty-four percent.
Alex: But that's proved by watching hundreds of thousands of real people over time.
Bill: Not a petri dish. And the Newcastle study is asking a different question entirely — not "does exercise reduce cancer risk?" but "what's one possible mechanism that might partially explain why?" That's a worthwhile question. It's just not a clinical finding. It's a clue.
Alex: And even as a clue, it's a narrow one — the study only tested the acute response to a single ten-minute session. Thirty healthy people who didn't have cancer. No chronic effect measured, no cancer patients, no immune system involvement, the whole thing outside the body. That's a lot of gaps between "serum changed gene expression in a dish" and "exercise fights cancer."
Bill: The research itself acknowledges this — it's exploratory, mechanistic, a first step. And honestly? I have a lot of respect for the paper's own language. The authors don't overclaim. It's the kind of thing that belongs at a biochemistry conference as a promising preliminary finding. Not plastered across every wellness platform as a breakthrough.
Alex: So what do we actually take away?
Bill: Here's where I land. Exercise genuinely does reduce cancer risk — that's real, supported by decades of population data. This study offers one small potential piece of the puzzle for how. But we are many, many steps away from knowing whether these specific molecular signals matter clinically in humans. The petri dish is the beginning of a long road.
Alex: And for anyone listening who's hoping this means ten minutes on a bike could treat cancer — that is not what this shows. Not yet, and possibly not ever, depending on how future research goes.
Bill: The thing to watch for in future stories: any time a headline makes a strong clinical claim, check whether the underlying study was done in cells, in animals, or in actual humans with the condition being described. If it's cells or animals, the story needs the word "preliminary" stamped across it.
Alex: And look for the conditionals in the original research — "could," "might," "may" — because scientists use those words carefully. When a headline removes them, it's removing the actual scientific meaning.
Bill: The research is worth being interested in. Worth following. It's just not worth changing your treatment plan over — because it was never about treatment at all.
Alex: Exercise because the evidence genuinely supports it. Not because of one petri dish in Newcastle, however exciting the headlines made it sound.